Careers  |  Sign In  |  Register

Carboplatin-Pemetrexed Effective for Elderly Patients With Non-small Cell Lung Cancer


Based on results from an earlier study led by Dr Isamu Okamoto of the Graduate School of Medical Sciences at Kyushu University in Fukuoka, Japan that found progression-free survival and response rates in elderly patients with advanced non-small cell lung cancer (NSCLC) were better with docetaxel when compared with vinorelbine, the research team initiated a subsequent non-inferiority phase-3 randomized clinical trial which consisted of treatment with carboplatin plus pemetrexed followed by pemetrexed maintenance therapy compared with docetaxel monotherapy in cytotoxic chemotherapy-naive patients 75 years or older with advanced non-squamous NSCLC. In the 433 patients enrolled, median follow-up time of 17.1 months yielded overall survival data in the carboplatin-pemetrexed group of 74.5% which was non-inferior to that in the docetaxel group (77.0%).

To learn more, click here

Read the study publication in JAMA Oncology by clicking here.